Video
Dr. Kumar on Updates to Treatment for Patients With High-Risk Myeloma
Author(s):
Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.
Shaji Kumar, MD, professor of medicine, chair of the Myeloma, Amyloidosis, Dysproteinema Group, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.
Multiple myeloma is a very heterogenous disease; although the median overall survival has improved, one-quarter of patients will still die within the first 3 to 4 years, Kumar explainns. The high-risk nature of the disease in some patients seems to be primarily driven by genetic abnormalities, as well as other tumor characteristics. Moreover, patients may present with standard-risk disease but then, over time, they can progress to higher-risk disease and require different treatment.
Researchers in the field have made strides in working to change therapy in their assessments of patients with high-risk multiple myeloma.
<<< View more from the 2017 Chemotherapy Foundation Symposium
